Alnylam Pharmaceuticals
- Market cap
- 30.03B
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Div yieldi
- 0.00%
- 52W posi
- 9%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Alnylam Pharmaceuticals closed at 224.41, up 0.21%. That leaves the company valued at approximately 30.03B, the #627 most valuable US-listed company we track. Valuation-wise, the P/E sits at 42.99, 136% above the five-year average of 18.21. Wall Street's 21-analyst consensus lands on Buy, with a price target averaging 369.96 (+65% from here). The shares sit 9% of the way up their 52-week range of 197.81 to 495.55.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Its last 6 Sell calls were actually followed by a +3% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -40.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 5.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 38.3x | Better than 18% |
| Forward P/E | 29.2x | Better than 22% |
| Price / Sales | 6.9x | Better than 19% |
| P/E vs own 5-yr range | 84th pctl | Better than 21% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 81.6% | Better than 93% |
| Operating margin | 13.5% | Better than 46% |
| Net margin | 8.4% | Better than 40% |
| Return on equity | 73.3% | Better than 94% |
| Return on invested capital | 26.3% | Better than 91% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -31.6% | Better than 3% |
| 6-month return | -31.2% | Better than 4% |
| 12-month return (ex latest month) | -41.1% | Better than 4% |
| Distance below 52-week high | 55.6% | Better than 4% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.8x | Better than 79% |
| Debt to assets | 25.7% | Better than 57% |
| Interest coverage | 2.3x | Better than 22% |
| Free cash flow / net income | 148.3% | Better than 72% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 85.7% | Better than 66% |
| Upside to average target | 68.2% | Better than 90% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 223.94
- Open
- 224.39
- Day range
- 222.46 - 230.42
- Avg price
- 225.97
- Volume
- 1.06M
- Turnover
- 240.46M
- Turnover ratei
- 0.80%
- Volume ratioi
- 0.72
- Amplitudei
- 3.56%
- 52-week rangei
- 197.81 - 495.55
Valuation
- P/Ei
- 96.31
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Book value / shi
- 10.12
- Net profit
- 311.78M
- Net assets
- 1.35B
Share structure
- Market cap
- 30.03B
- Float capi
- 29.90B
- Shares out
- 133.81M
- Float sharesi
- 133.24M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
54.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+96.23M net over the window
Short interest
- Shares short
- 7.19M
- % of floati
- 5.38%
- Days to coveri
- 4.13
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
Alnylam Pharmaceuticals last traded at 224.41. The quote on this page refreshes every few seconds while US markets are open.
What is Alnylam Pharmaceuticals's market cap?
About 30.03B.
What is the P/E ratio of Alnylam Pharmaceuticals?
The trailing twelve-month P/E is 39.10, above its own 5-year average of 18.21 — toward the top of its historical range (84.11% percentile). See the Valuation tab for the full history.
Does Alnylam Pharmaceuticals pay a dividend?
Alnylam Pharmaceuticals does not currently pay a regular dividend.
Is Alnylam Pharmaceuticals a buy according to analysts?
The consensus of 21 analysts is a Buy rating, with an average 12-month price target of 369.96, which implies 64.9% upside from the current price. This is not investment advice.
What is Alnylam Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Alnylam Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-10-08 06:56:41 · For reference only, not investment advice and not tailored to your situation.